Editas Medicine (EDIT) Debt to Equity (2024 - 2025)
Editas Medicine (EDIT) reported Debt to Equity of $2.15 for Q4 2025, up 402.09% year-over-year from $0.43 in Q4 2024, and down 51.09% on a QoQ basis from $4.39 in Q3 2025.
Editas Medicine (EDIT) has 2 years of Debt to Equity data on file, last reported at $2.15 in Q4 2025.
- Quarterly Debt to Equity rose 402.09% year-over-year to $2.15 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.15 (up 402.09% YoY) and the FY2025 annual result came in at $2.15, up 402.09% from the prior year.
- Debt to Equity slipped to $2.15 in Q4 2025 per EDIT's latest filing, from $4.39 in the prior quarter.
- Across five years, Debt to Equity topped out at $4.39 in Q3 2025 and bottomed at $0.43 in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt/Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 0.06 |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Editas Medicine | 338.62 Mn | 338.62 Mn | - | 2.15 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.15 |
| Sep 30, 2025 | 4.39 |
| Jun 30, 2025 | 2.95 |
| Mar 31, 2025 | 0.87 |
| Dec 31, 2024 | 0.43 |